Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
2.
Hong Kong Med J ; 23(1): 13-8, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27909267

RESUMO

INTRODUCTION: There are two antivenoms that may be administered in Hong Kong following a bite by Trimeresurus albolabris: the green pit viper antivenom from the Thai Red Cross Society in Thailand and the Agkistrodon halys antivenom from the Shanghai Institute of Biological Products in China. Both are recommended by the Central Coordinating Committee of Accident and Emergency Services of the Hospital Authority for treating patients with a bite by Trimeresurus albolabris. The choice of which antivenom to use is based on physician preference. This study aimed to compare the relative efficacy of the two antivenoms. METHODS: This in-vitro experimental study was carried out by a wildlife conservation organisation and a regional hospital in Hong Kong. Human plasma from 40 adult health care worker volunteers was collected. The Trimeresurus albolabris venom was added to human plasma and the mixture was assayed after incubation with each antivenom (green pit viper and Agkistrodon halys) using saline as a control. Fibrinogen level and clotting time in both antivenom groups were studied. RESULTS: The mean fibrinogen level was elevated from 0 g/L to 2.86 g/L and 1.11 g/L after the addition of green pit viper antivenom and Agkistrodon halys antivenom, respectively. When mean clotting time was measured, the value was 6.70 minutes in the control, prolonged to more than 360 minutes by green pit viper antivenom and to 19.06 minutes by Agkistrodon halys antivenom. CONCLUSIONS: Green pit viper antivenom was superior to Agkistrodon halys antivenom in neutralisation of the thrombin-like and hypofibrinogenaemic activities of Trimeresurus albolabris venom.


Assuntos
Antivenenos/farmacologia , Coagulação Sanguínea/efeitos dos fármacos , Venenos de Crotalídeos/antagonistas & inibidores , Adulto , Testes de Coagulação Sanguínea , China , Venenos de Crotalídeos/intoxicação , Voluntários Saudáveis , Hong Kong , Humanos , Mordeduras de Serpentes/terapia , Tailândia , Fatores de Tempo
3.
Blood Cancer J ; 6(7): e442, 2016 07 08.
Artigo em Inglês | MEDLINE | ID: mdl-27391574

RESUMO

Clinical outcome and mutations of 96 core-binding factor acute myeloid leukemia (AML) patients 18-60 years old were examined. Complete remission (CR) after induction was 94.6%. There was no significant difference in CR, leukemia-free-survival (LFS) and overall survival (OS) between t(8;21) (N=67) and inv(16) patients (N=29). Univariate analysis showed hematopoietic stem cell transplantation at CR1 as the only clinical parameter associated with superior LFS. Next-generation sequencing based on a myeloid gene panel was performed in 72 patients. Mutations in genes involved in cell signaling were associated with inferior LFS and OS, whereas those in genes involved in DNA methylation were associated with inferior LFS. KIT activation loop (AL) mutations occurred in 25 patients, and were associated with inferior LFS (P=0.003) and OS (P=0.001). TET2 mutations occurred in 8 patients, and were associated with significantly shorter LFS (P=0.015) but not OS. Patients negative for KIT-AL and TET2 mutations (N=41) had significantly better LFS (P<0.001) and OS (P=0.012) than those positive for both or either mutation. Multivariate analysis showed that KIT-AL and TET2 mutations were associated with inferior LFS, whereas age ⩾40 years and marrow blast ⩾70% were associated with inferior OS. These observations provide new insights that may guide better treatment for this AML subtype.


Assuntos
Fatores de Ligação ao Core/genética , Fatores de Ligação ao Core/metabolismo , Proteínas de Ligação a DNA/genética , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/metabolismo , Mutação , Proteínas Proto-Oncogênicas c-kit/metabolismo , Proteínas Proto-Oncogênicas/genética , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Terapia Combinada , Metilação de DNA , Análise Mutacional de DNA , Proteínas de Ligação a DNA/metabolismo , Dioxigenases , Feminino , Transplante de Células-Tronco Hematopoéticas/métodos , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Leucemia Mieloide Aguda/mortalidade , Leucemia Mieloide Aguda/terapia , Masculino , Pessoa de Meia-Idade , Prognóstico , Proteínas Proto-Oncogênicas/metabolismo , Proteínas Proto-Oncogênicas c-kit/genética , Transdução de Sinais , Análise de Sobrevida , Translocação Genética , Transplante Homólogo , Adulto Jovem
4.
Eur J Cancer Care (Engl) ; 24(1): 117-24, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25848698

RESUMO

We performed a retrospective study to analyse the characteristics and clinical outcomes of diffuse large B-cell lymphoma (DLBCL) patients with hepatitis B virus (HBV) infection and compare with those without HBV infection. The occurrence of hepatitis after withdrawal of prophylactic antiviral treatment on completion of chemotherapy was also assessed. The HBsAg-positive patients were given prophylactic antiviral treatment until 6 months after finishing chemotherapy. A total of 81 patients were recruited with 16 in the HBsAg-positive group and 65 in the HBsAg-negative group. The clinical characteristics were similar in both groups of patients. There was no significant difference in complete remission rate between the two groups (63% in HBsAg-positive group vs. 54% in HBsAg-negative group, P = 0.59). There was also no statistically significant difference in overall survival between the two groups (P = 0.23). Four of the 16 HBsAg-positive patients (25%) had hepatitis after cessation of chemotherapy and prophylactic lamivudine. The mean time of onset of hepatitis was 3 months after stopping lamivudine. In conclusion, HBV infection did not appear to affect the prognosis of DLBCL patients given antiviral prophylaxis. It is reasonable to consider prophylactic antiviral therapy to extend to at least one year on completion of chemotherapy.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Hepatite B/complicações , Lamivudina/uso terapêutico , Linfoma Difuso de Grandes Células B/complicações , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica , Feminino , Hepatite B/prevenção & controle , Vírus da Hepatite B/isolamento & purificação , Humanos , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Fatores de Risco , Rituximab/efeitos adversos , Rituximab/uso terapêutico , Análise de Sobrevida , Resultado do Tratamento , Adulto Jovem
5.
BMJ Case Rep ; 20132013 Aug 13.
Artigo em Inglês | MEDLINE | ID: mdl-23943810

RESUMO

We report the first case of McLeod syndrome (MLS) in a 47-year-old Chinese man who presented with progressive limb weakness, chorea of feet, red blood cell acanthocytosis, absence of Kx red blood cell antigen and weak expression of Kell antigens. The diagnosis of MLS was confirmed by genetic testing showing a hemizygous mutation of XK gene. We review literature on neuroacanthocytosis in the Chinese population.


Assuntos
Neuroacantocitose , Povo Asiático , Humanos , Masculino , Pessoa de Meia-Idade , Neuroacantocitose/diagnóstico
6.
Hong Kong Med J ; 17(3): 237-41, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21636872

RESUMO

Haemolytic uraemic syndrome is an important cause of acute renal impairment in childhood. We review the incidence, and clinical and laboratory features of haemolytic uraemic syndrome in a Chinese population. Five patients were identified from 2006 to 2008. All patients were young children with associated invasive Streptococcus pneumoniae pulmonary infection. Serotypes 3, 14, and 19A were confirmed in four patients. The classical post-diarrhoeal form associated with Escherichia coli (O157:H7) infection was not seen. One patient died of acute respiratory failure. Streptococcus pneumoniae infection, as an associated condition in haemolytic uraemic syndrome, is important and relatively common in Chinese patients, especially among children. The acute clinical picture is similar to that reported in the western literature, except for an uncommon association with meningitis. The medium-term renal outcome of the Chinese population appears to be more favourable than the Caucasians. Widespread vaccination against Streptococcus pneumoniae may have resulted in changes in bacterial epidemiology and clinicians should be continuously aware of this severe disease. The use of washed blood components for transfusion in the acute stage requires further study.


Assuntos
Síndrome Hemolítico-Urêmica/microbiologia , Infecções Pneumocócicas/complicações , Streptococcus pneumoniae/isolamento & purificação , Pré-Escolar , China , Feminino , Seguimentos , Humanos , Masculino , Infecções Pneumocócicas/microbiologia , Insuficiência Respiratória/microbiologia , Infecções Respiratórias/microbiologia , Estudos Retrospectivos , Sorotipagem , Índice de Gravidade de Doença , Streptococcus pneumoniae/classificação
7.
Arthritis Rheum ; 63(5): 1182-9, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21391198

RESUMO

OBJECTIVE: To examine the life expectancy, standardized mortality ratios (SMRs), and causes of death in 6 groups of patients from Hong Kong with different rheumatic diseases. METHODS: Patients with a diagnosis of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic vasculitis (SV), or systemic sclerosis (SSc) registered in 37 public hospitals between 1999 and 2008 were identified in the hospital registry. SMRs were calculated by comparing the mortality rate in patients with each disease with that in the general population. Life expectancy was calculated by abridged life-table analysis, and the causes of death were compared. RESULTS: In 2008, data on 8,367 RA, 5,243 SLE, 2,154 AS, 1,636 SV, 778 PsA, and 449 SSc patients were available in our registry. The age- and sex-adjusted SMRs were highest for SLE (5.25 [95% confidence interval 4.79-5.70]), SSc (3.94 [95% confidence interval 3.20-4.68]), and SV (2.64 [95% confidence interval 2.36-2.93]). In female patients, the loss in life expectancy was greatest for SSc (34.1 years), SV (19.3 years), and SLE (19.7 years). In male patients, the loss in life expectancy was highest for SV (28.3 years), SLE (27 years), and SSc (16 years). There were 2,486 deaths during the study period (1999-2008), and the principal causes were infections (28%), cardiovascular complications (18%), cancer (16%), and disease activity (7%). Infection was the leading cause of death in SLE, RA, AS, and PsA, whereas deaths from disease-related activity and cardiovascular complications were most frequent in SSc. Cancer was the most common cause of death in SV. CONCLUSION: Our findings indicate that patients with SLE, RA, AS, PsA, SV, and SSc have increased mortality rates and reduced life expectancy. SLE has the highest adjusted SMR, and female SSc patients have the greatest loss in life expectancy. Infection is the leading cause of death, followed by cardiovascular complications and malignancies.


Assuntos
Expectativa de Vida , Doenças Reumáticas/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Causas de Morte , Distribuição de Qui-Quadrado , Feminino , Hong Kong/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Fatores Sexuais
8.
Neurology ; 75(24): 2185-9, 2010 Dec 14.
Artigo em Inglês | MEDLINE | ID: mdl-21172841

RESUMO

BACKGROUND: The association between protein S deficiency (PSD) and ischemic stroke is controversial and warrants further investigation. METHODS: We conducted a genotype and MRI correlation study in a Chinese family in which hereditary PSD cosegregated with premature ischemic strokes. Six out of 11 family members inherited PSD type III in an autosomal dominant manner. RESULTS: Among all PSD members, a novel missense mutation 1063C→T in exon 10 of protein S alpha (PROS1) was identified, which encoded a substitution of arginine to cysteine at position 355 (R355C) in the first globular domain of laminin A of protein S. Wild-type PROS1 sequences were retained in non-PSD members. MRI detected deep white matter infarctions predominantly distributed in the borderzone regions. The infarct topography was homogeneous in all adult mutant carriers. By contrast, cerebral infarction was absent in nonmutant carriers. Extensive investigation in the family did not reveal any confounding stroke risk. Haplotype analysis with high-density single nucleotide polymorphism markers revealed a 6.1-Mb minimally rearranged region (rs12494685 to rs1598240) in 3q11.2, lod = 3.0. Among the 7 annotated genes in this region, PROS1 is known to be associated with thrombotic disorders. MRI screening in an additional 10 PSD families without R355C showed no cerebral infarction. CONCLUSIONS: PROS1 R355C mutation cosegregated with PSD type III and premature white matter infarctions in the index family. The findings substantiate an association between PSD and stroke. Study of the mechanism underlying this association may improve our understanding of premature cryptogenic white matter infarction.


Assuntos
Encéfalo/patologia , Infarto Cerebral/genética , Infarto Cerebral/patologia , Mutação de Sentido Incorreto , Deficiência de Proteína S/complicações , Proteína S/genética , Adolescente , Adulto , Idoso , Arginina , Encéfalo/irrigação sanguínea , Criança , Cisteína , Feminino , Predisposição Genética para Doença , Haplótipos , Hong Kong , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Anotação de Sequência Molecular , Linhagem , Polimorfismo de Nucleotídeo Único , Fatores de Risco , Adulto Jovem
9.
Hong Kong Med J ; 15(5): 365-73, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19801694

RESUMO

Imatinib is the standard treatment for chronic myeloid leukaemia. BCR-ABL kinase domain mutation is the commonest mechanism implicated in imatinib resistance. In in-vitro studies, kinase domain mutations are variably resistant to second-line agents. We performed BCR-ABL kinase domain mutational studies in 25 patients in five institutions who failed imatinib and were treated with either nilotinib or dasatinib, to see if their mutational status would predict their clinical responses. Kinase domain mutations involving 11 amino acid substitutions were found in 12 (48%) patients. Most patients showed single kinase domain mutations. There was some concordance between reported drug sensitivity patterns and patient responses. Discordant responses could be related to drug dosage variations and unknown BCR-ABL independent mechanisms. The response prediction for patients with multiple kinase domain mutations was challenging and their mutational patterns could change after tyrosine kinase inhibitor therapy. Although BCR-ABL kinase domain mutational analysis has limitations as a means of predicting the clinical response to second-line tyrosine kinase inhibitors, it helps inform therapy decisions in the management of chronic myeloid leukaemia after imatinib failure.


Assuntos
Proteínas de Fusão bcr-abl/genética , Leucemia Mielogênica Crônica BCR-ABL Positiva/genética , Inibidores de Proteínas Quinases/farmacologia , Proteínas Tirosina Quinases/genética , Substituição de Aminoácidos , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Benzamidas , Dasatinibe , Resistencia a Medicamentos Antineoplásicos/genética , Humanos , Mesilato de Imatinib , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Mutação , Piperazinas/farmacologia , Piperazinas/uso terapêutico , Inibidores de Proteínas Quinases/uso terapêutico , Pirimidinas/farmacologia , Pirimidinas/uso terapêutico , Estudos Retrospectivos , Tiazóis/farmacologia , Tiazóis/uso terapêutico , Resultado do Tratamento
10.
Leukemia ; 23(8): 1490-9, 2009 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19262598

RESUMO

Chromosomal rearrangements of the human MLL gene are associated with high-risk pediatric, adult and therapy-associated acute leukemias. These patients need to be identified, treated appropriately and minimal residual disease was monitored by quantitative PCR techniques. Genomic DNA was isolated from individual acute leukemia patients to identify and characterize chromosomal rearrangements involving the human MLL gene. A total of 760 MLL-rearranged biopsy samples obtained from 384 pediatric and 376 adult leukemia patients were characterized at the molecular level. The distribution of MLL breakpoints for clinical subtypes (acute lymphoblastic leukemia, acute myeloid leukemia, pediatric and adult) and fused translocation partner genes (TPGs) will be presented, including novel MLL fusion genes. Combined data of our study and recently published data revealed 104 different MLL rearrangements of which 64 TPGs are now characterized on the molecular level. Nine TPGs seem to be predominantly involved in genetic recombinations of MLL: AFF1/AF4, MLLT3/AF9, MLLT1/ENL, MLLT10/AF10, MLLT4/AF6, ELL, EPS15/AF1P, MLLT6/AF17 and SEPT6, respectively. Moreover, we describe for the first time the genetic network of reciprocal MLL gene fusions deriving from complex rearrangements.


Assuntos
Leucemia/genética , Proteína de Leucina Linfoide-Mieloide/genética , Proteínas de Neoplasias/genética , Proteínas de Fusão Oncogênica/genética , Recombinação Genética , Translocação Genética , Doença Aguda , Adulto , Biópsia , Medula Óssea/química , Medula Óssea/patologia , Criança , Quebra Cromossômica , Cromossomos Humanos Par 11/genética , Cromossomos Humanos Par 11/ultraestrutura , Biologia Computacional , DNA de Neoplasias/sangue , DNA de Neoplasias/genética , Duplicação Gênica , Histona-Lisina N-Metiltransferase , Humanos , Reação em Cadeia da Polimerase
15.
Hong Kong Med J ; 11(5): 411-3, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16219964

RESUMO

We report the successful treatment of infective endocarditis caused by Streptococcus mitis with linezolid in a patient with pre-existing valvular heart disease. The patient had multiple allergies to conventional antibiotics. Linezolid may provide an oral alternative in the treatment of infective endocarditis in patients with adverse drug reactions to traditional antibiotic regimens.


Assuntos
Acetamidas/uso terapêutico , Anti-Infecciosos/uso terapêutico , Endocardite Bacteriana/tratamento farmacológico , Oxazolidinonas/uso terapêutico , Infecções Estreptocócicas/tratamento farmacológico , Streptococcus mitis/isolamento & purificação , Adulto , Endocardite Bacteriana/microbiologia , Humanos , Linezolida , Masculino , Infecções Estreptocócicas/microbiologia
16.
Spinal Cord ; 41(6): 359-64, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12746743

RESUMO

STUDY DESIGN: Case report. OBJECTIVE: To describe the clinical presentations, radiological features and clinical progress of a rare case of chondroblastoma of the lumbar spine. SETTING: Regional Hospital, Hong Kong, China. METHOD: A 54-year-old male patient presented with low back pain and left sciatica. X-ray and MRI revealed tumour infiltration of the fifth lumbar vertebrae and left paraspinal muscles, which was found to be a chondroblastoma by repeated open biopsies. The tumour was removed surgically by combined anterior and posterior approaches, followed by spinal fusion and instrumentation. RESULTS: The anterior tricortical bone graft was complicated with fracture and nonunion. Surgical re-exploration confirmed local recurrence of tumour macroscopically and histologically. The patient developed symptoms and signs of cauda equina syndrome gradually despite repeated surgery and irradiation. The patient eventually died of complications of local recurrence and neurological deficit at 3 years and 8 months after the first operation. CONCLUSION: This is the first case report of chondroblastoma of the lumbar spine. The clinical profile of this patient and the evidence from the literature review suggests that spinal chondroblastoma has a very aggressive behaviour with high recurrence and mortality rate.


Assuntos
Neoplasias Ósseas/complicações , Condroblastoma/complicações , Vértebras Lombares , Polirradiculopatia/complicações , Neoplasias Ósseas/mortalidade , Neoplasias Ósseas/patologia , Neoplasias Ósseas/cirurgia , Condroblastoma/mortalidade , Condroblastoma/patologia , Condroblastoma/cirurgia , Humanos , Imageamento por Ressonância Magnética/métodos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Polirradiculopatia/mortalidade , Polirradiculopatia/patologia , Complicações Pós-Operatórias/mortalidade , Fusão Vertebral/métodos , Tomografia Computadorizada por Raios X/métodos
17.
Ann Oncol ; 14(5): 752-7, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12702530

RESUMO

BACKGROUND: The best overall treatment strategy for patients with acute promyelocytic leukaemia (APL) in relapse with chemotherapy, bone marrow transplantation (BMT) or arsenic trioxide (As(2)O(3)) based therapy remains undefined. PATIENTS AND METHODS: We reviewed the clinical course and treatment outcome of 143 APL cases seen in four major hospitals in Hong Kong over a 10-year period. RESULTS: Complete remission (CR) was attained in 113 cases (79%) with all-trans retinoic acid (ATRA) and chemotherapy. Relapse occurred at a median of 16 months in 54 cases, with a 3-year disease free survival of 56%. Post-relapse treatment was successful in 41 cases (76%), giving an actuarial 3-year overall survival (OS) of 81% from CR1. Three different protocols were used: chemotherapy alone (n = 19), allogeneic BMT (n = 14) and an As(2)O(3)-based regimen (n = 21). Chemotherapy was associated with the highest treatment-related mortality (TRM) at 53%, giving a CR2 rate of 47%. TRM was 36% for BMT. The CR2 rate for the As(2)O(3)-based regimen was 100%, with no TRM. However, 38% of As(2)O(3) treated patients had subsequent relapses, which were further salvaged in 75% by combined As(2)O(3) plus ATRA. The actuarial OS for the three protocols leveled off by 2 years at 82% for As(2)O(3), 43% for BMT and 23% for chemotherapy (P = 0.0004). CONCLUSIONS: Our results suggest that As(2)O(3) may be superior to chemotherapy and BMT for the treatment of APL in relapse.


Assuntos
Arsenicais/uso terapêutico , Transplante de Medula Óssea/estatística & dados numéricos , Leucemia Promielocítica Aguda/tratamento farmacológico , Leucemia Promielocítica Aguda/terapia , Óxidos/uso terapêutico , Adolescente , Adulto , Trióxido de Arsênio , Criança , Feminino , Humanos , Leucemia Promielocítica Aguda/mortalidade , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Prevenção Secundária , Taxa de Sobrevida
18.
Cancer Genet Cytogenet ; 142(1): 77-9, 2003 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-12660039

RESUMO

Clonal proliferation of T-cell large granular lymphocytes (LGL) is an indolent disorder characterized by splenomegaly, lymphocytosis and frequent manifestations of immune disturbances. The LGL are CD3(+) CD4(-) CD8(+) CD56(-). The clonality of the tumor cell population is often only demonstrable by T-cell receptor (TCR) gene rearrangement study because chromosomal abnormality is distinctly rare. We describe a case of T-cell LGL leukemia that presented initially as cytomegalovirus infection. The leukemic LGL are shown to be clonal by both TCR gene rearrangement and chromosomal studies. They persist after subsidence of the cytomegalovirus infection.


Assuntos
Infecções por Citomegalovirus/patologia , Rearranjo Gênico do Linfócito T , Leucemia Linfoide/patologia , Linfocitose/patologia , Linfócitos T/patologia , Adulto , Complexo CD3/metabolismo , Linfócitos T CD4-Positivos/fisiologia , Antígeno CD56/metabolismo , Antígenos CD8/metabolismo , Células Clonais/imunologia , Células Clonais/patologia , Análise Citogenética , Infecções por Citomegalovirus/complicações , Diagnóstico Diferencial , Seguimentos , Humanos , Cariotipagem , Leucemia Linfoide/diagnóstico , Leucemia Linfoide/etiologia , Linfocitose/diagnóstico , Linfocitose/etiologia , Masculino , Receptores de Antígenos de Linfócitos T gama-delta/genética , Linfócitos T/imunologia
19.
Ann Hematol ; 81(3): 167-9, 2002 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11904745

RESUMO

We describe a case of acute myeloid leukemia (AML) with abnormal eosinophils in a 44-year-old Chinese woman that was complicated by diffuse alveolar damage (DAD) and pulmonary hemorrhage (PH) shortly after induction chemotherapy. Cytogenetic study of bone marrow cells at diagnosis showed a rare aberration of trisomy X (+X) as the sole acquired karyotypic abnormality. We speculate that tissue damage by cellular constituents of the abnormal eosinophils that were released on cell lysis after chemotherapy might be etiologically linked to the occurrence of fatal pulmonary complications.


Assuntos
Eosinófilos/patologia , Leucemia Mieloide/genética , Leucemia Mieloide/patologia , Alvéolos Pulmonares/patologia , Trissomia/genética , Cromossomo X/genética , Doença Aguda , Adulto , Evolução Fatal , Feminino , Hemorragia/complicações , Humanos , Leucemia Mieloide/complicações , Pneumopatias/complicações
20.
Cancer Genet Cytogenet ; 139(1): 52-6, 2002 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-12547159

RESUMO

We describe two novel chromosomal translocations in two cases of leukemia in which these translocations were further characterized as the sole acquired karyotypic abnormality by mutliplex fluorescence in situ hybridization (M-FISH). They comprised a case of acute myeloid leukemia with t(6;10)(q21;p12) and a case of chronic myelomonocytic leukemia with t(5;12)(q34;q24). To the best of our knowledge, these two balanced translocations are novel and are hitherto unrecognized in hematologic malignancies. While the clinical and pathogenic significance of these translocations remains to be defined, the present report illustrates that M-FISH technology contributes to the exclusion of subtle or cryptic translocations in sole karyotypic aberrations and the confirmation of novel chromosomal arrangements in neoplastic disorders.


Assuntos
Cromossomos Humanos Par 10 , Cromossomos Humanos Par 6 , Leucemia Mieloide Aguda/genética , Translocação Genética , Mapeamento Cromossômico , Cromossomos Humanos Par 12 , Cromossomos Humanos Par 5 , Humanos , Hibridização in Situ Fluorescente/métodos , Cariotipagem , Leucemia Mielomonocítica Crônica/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA